Walleye Capital LLC Grows Stake in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Walleye Capital LLC significantly increased its stake in AMNEAL PHARMACEUTICALS, acquiring an additional 519,863 shares, bringing its total to 558,842 shares worth approximately $4.68 million.
• Other institutional investors also boosted their holdings, with Vanguard Group Inc. increasing its stake by 6.2% to own over 15 million shares valued at $132 million.
• AMNEAL PHARMACEUTICALS has received a mix of ratings from analysts, with a consensus rating of "Buy" and an average price target of $11.60.

Walleye Capital LLC increased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1,333.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 558,842 shares of the company's stock after buying an additional 519,863 shares during the period. Walleye Capital LLC owned 0.18% of Amneal Pharmaceuticals worth $4,683,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AMRX. Vanguard Group Inc. raised its holdings in shares of Amneal Pharmaceuticals by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after acquiring an additional 920,758 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 5.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock valued at $39,531,000 after purchasing an additional 278,653 shares in the last quarter. BlackBarn Capital Partners LP raised its stake in Amneal Pharmaceuticals by 1.1% during the first quarter. BlackBarn Capital Partners LP now owns 2,881,654 shares of the company's stock valued at $24,148,000 after purchasing an additional 31,654 shares in the last quarter. Nuveen LLC purchased a new stake in Amneal Pharmaceuticals during the first quarter valued at $19,581,000. Finally, Invesco Ltd. raised its position in shares of Amneal Pharmaceuticals by 19.2% during the 1st quarter. Invesco Ltd. now owns 2,272,713 shares of the company's stock valued at $19,045,000 after buying an additional 365,467 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the transaction, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the transaction, the executive vice president directly owned 152,743 shares in the company, valued at approximately $1,475,497.38. The trade was a 42.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 609,206 shares of company stock worth $5,700,625. Company insiders own 26.56% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AMRX. The Goldman Sachs Group began coverage on shares of Amneal Pharmaceuticals in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $11.60.

Amneal Pharmaceuticals Stock Performance

AMRX stock traded up $0.01 during midday trading on Friday, reaching $9.56. The company's stock had a trading volume of 2,493,976 shares, compared to its average volume of 1,653,499. The stock has a fifty day simple moving average of $8.52 and a two-hundred day simple moving average of $8.07. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.79. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 956.96 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.